Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16996409 | 0.96 | KDM4E (0.36) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL16996117 | 0.95 | MEN1 (0.36) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL17854151 | 0.93 | KDM4E (0.32) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL21558949 | 0.93 | KDM4E (0.32) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL808395 | 0.93 | KDM4E (0.36) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL21559207 | 0.93 | KDM4E (0.38) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL17903069 | 0.93 | MEN1 (0.38) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL15213719 | 0.93 | KDM4E (0.35) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL23597862 | 0.92 | SIGMAR1 (0.35) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL808072 | 0.92 | SIGMAR1 (0.35) | KDM4EMEN1LMNAMAPTOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567026-B1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | LG CHEMICAL LTD (KR) | 2021-12-29 | — | — | EP | disclosed |
| US-20200131112-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2020-04-30 | — | — | US | disclosed |
| EP-3567026-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | LG Chem, Ltd. (KR) | 2019-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131112-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | AOX1, CYP1B1, CRY1 | KDM4E 2434/4885MEN1 558/4885LMNA 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.